Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Respiratory Syncytial Virus Disease

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

Common Respiratory Disorders

Common Respiratory Disorders

Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...

Chickenpox

Chickenpox

Chickenpox is an acute, highly contagious disease caused by the varicella-zoster virus (VZV), a double-stranded DNA virus belonging to the Herpesviridae family. Its transmission occurs primarily through the inhalation of respiratory droplets or direct contact with vesicular fluid from skin lesions. The incubation period typically ranges from 10 to 21 days, during which the virus replicates and disseminates through sequential phases within the host. Although generally self-limiting in children,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical-grade autonomous cytopathology through whole-slide edge tomography.

Nature·2026

Same author

Characterization of POU2F3-expressing large cell neuroendocrine carcinoma of the lung: A comprehensive analysis of morphology, immunohistochemistry, and genomic alterations.

Cancer treatment and research communications·2026

Same author

Clinicopathologic, Cellular, and Molecular Analyses of Pulmonary Neuroendocrine Carcinoma With High Expression of Hepatocyte Nuclear Factor 4 Alpha.

Laboratory investigation; a journal of technical methods and pathology·2025

Same author

Antiviral target compound profile for pandemic preparedness.

Nature reviews. Drug discovery·2024

Same author

High expression of eukaryotic elongation factor 1-alpha-2 in lung adenocarcinoma is associated with poor prognosis.

Pathology international·2024

Same author

Letermovir safety and efficacy for cytomegalovirus prophylaxis in adult Japanese kidney transplant recipients: a multicenter, open-label, noncomparative Phase 3 study.

Clinical and experimental nephrology·2024

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Respiratory syncytial virus vaccine development.

Yoshihiko Murata¹

¹Division of Infectious Diseases, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA. Yoshihiko_Murata@urmc.rochester.edu

Clinics in Laboratory Medicine

|November 7, 2009

Summary

Developing a safe and effective respiratory syncytial virus (RSV) vaccine remains a challenge. This review examines 40 years of progress in RSV vaccine research, including various experimental approaches and their clinical development.

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

Related Experiment Videos

Last Updated: Jun 19, 2026

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

Area of Science:

Virology
Immunology
Vaccinology

Background:

Respiratory syncytial virus (RSV) causes significant respiratory illness, particularly in infants, the elderly, and immunocompromised individuals.
Currently, no licensed prophylactic vaccine is available for RSV, despite the substantial disease burden.
Early vaccine development attempts using formalin-inactivated RSV led to enhanced disease in children.

Purpose of the Study:

To review the scientific rationale, preclinical testing, and clinical development of various RSV vaccine candidates.
To provide an overview of the progress made in RSV vaccine development over the past 40 years.

Main Methods:

Review of scientific literature on RSV vaccine development.
Analysis of experimental approaches including live attenuated strains, vector-based vaccines, and subunit/DNA-based vaccines.
Examination of preclinical and clinical trial data for different vaccine candidates.

Main Results:

Multiple experimental approaches have been explored for RSV vaccine development.
Progress has been cautious due to challenges encountered in earlier trials.
Various strategies are under investigation, including live attenuated, vector-based, and subunit vaccines.

Conclusions:

Significant challenges remain in developing a licensed prophylactic RSV vaccine.
Diverse vaccine platforms are being pursued, showing cautious but deliberate progress.
Continued research into novel approaches is essential for future RSV vaccine success.